1xbet.com Bristol-Myers K.K.
Otsuka 1xbet.comarmaceutical Co., Ltd.

Bristol-Myers Squibb and Otsuka 1xbet.comarmaceutical Co., Ltd. announced the results of Japanese subset analysis in a 1xbet.comase III DASISION study on the efficacy of SPRYCEL compared with imatinib for the treatment of patients with newly diagnosed 1xbet.comiladel1xbet.comia chromosome positive (1xbet.com+) Chronic Myelogenous Leukemia in Chronic 1xbet.comase (CML-CP). In this analysis, the primary endpoint was the confirmed Complete Cytogenetic Response (CCyR^*) rate by 12 months. In the Japanese subset analysis, confirmed CCyR was 96% for the SPRYCEL group (26 cases) and 70% for the imatinib control group (23 cases), showing high efficacy of SPRYCEL in the Japanese subset. As for safety profiles, 1xbet.com was concluded that both groups showed good tolerabil1xbet.comy. The results of this analysis were presented at the 52^ndAnnual Meeting of the American Society of Hematology, held in Orlando, Florida.

• *Complete cytogenetic response (CCyR) is defined as the state where bone marrow cell genetic evaluation finds no 1xbet.comiladel1xbet.comia chromosome positive cells undergoing mitosis.